Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Fulvestrant 10Letrozole 4Alpelisib 4ribociclib 3palbociclib 3Paclitaxel 2NVP-BKM120 2volagidemab 1serabelisib 1sapanisertib 1olaparib 1liposomal doxorubicin 1gedatolisib 1exemestane 1dapagliflozin 1capivasertib 1abemaciclib 1Taxes 1Tamoxifen 1Secretin 1STX-478 1Metformin 1Lomustine 1Leuprolide 1Irinotecan 1Imlunestrant 1Goserelin 1Gemcitabine 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × sapanisertib × Breast × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡